Argus Pharmaceuticals Inc., Genzyme preclinical data

ARGS (The Woodlands, Texas) announced that its liposomal intravenous formulation potentially overcomes rapid removal of the drug, which has been an obstacle to its use in leukemia.

Over time, the body appears to develop a clearing mechanism that rapidly removes the drug from the body. But using ARGS's formulation, sustained blood levels were achieved in an animal model. As published in Leukemia Research, liver microsomes from rats did not change their metabolism of the drug, compared to speeded metabolism in microsomes from orally treated animals. ...